重症肌无力相关抗体的研究进展

作为一种累及神经肌肉接头的自身免疫性疾病,重症肌无力(myasthenia gravis,MG)的发病机制与自身免疫性抗体密切相关。关于MG相关抗体,研究最多且最为明确的是乙酰胆碱受体抗体(acetylcholine receptor antibody,AChR-Ab),由于存在AChR-Ab阴性的MG患者,近年来学者们开始热衷于研究AChR-Ab以外的其他抗体,如肌肉特异性酪氨酸激酶抗体、低密度脂蛋白4抗体等,并进行相应治疗方案的探索。该文对MG相关抗体的研究进展进行综述,为今后治疗该病提供临床依据和参考。

Advances in the study of antibodies associated with myasthenia gravis

As an autoimmune disease involving the neuromuscular junction,the pathogenesis of myasthenia gravis(MG)is closely related to autoimmune antibodies.Regarding related antibodies,acetylcholine receptor antibody(AChR-Ab)is the most studied and clear.In recent years,researchers have began to study antibodies other than AChR-Ab due to the presence of AChR-Ab-negative MG patients,such as muscle-specific tyrosine kinase antibodies,low-density lipoprotein 4 antibodies,and explore the corresponding treatment options.This article reviewed the research progress of MG related antibodies,and provided clinical evidence and reference for the future treatment of this disease.